Modality
Small Molecule
MOA
MDM2i
Target
BCMA
Pathway
Amyloid
Cervical Ca
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
~Mar 2023
→ ~Jun 2024
Phase 3
Sep 2024
→ Mar 2030
Phase 3Current
NCT03958503
2,941 pts·Cervical Ca
2024-09→2030-03·Recruiting
2,941 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-013.9y awayPh3 Readout· Cervical Ca
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Recruit…
Catalysts
Ph3 Readout
2030-03-01 · 3.9y away
Cervical Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03958503 | Phase 3 | Cervical Ca | Recruiting | 2941 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Capiglumide | BioNTech | Preclinical | CGRP |